Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
118 hedge funds and large institutions have $246M invested in Insys Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 18 closing their positions.
13% more capital invested
Capital invested by funds: $218M → $246M (+$28.8M)
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% more funds holding
Funds holding: 116 → 118 (+2)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
30% less call options, than puts
Call options by funds: $4.05M | Put options by funds: $5.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$7.5M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.36M |
| 3 |
O
OrbiMed
New York
|
+$1.18M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$937K |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
+$822K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCP
Fine Capital Partners
New York
|
-$4.76M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.57M |
| 3 |
FHAM
Folger Hill Asset Management
New York
|
-$2.67M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$2.55M |
| 5 |
Millennium Management
New York
|
-$2.29M |
INSY Hedge Fund Activity: Q2 2017 in Review
118 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2017, worth a combined $246M — up 13% from $218M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new INSY positions and 18 closed out — a net gain of 2 holders — while 34 added to existing stakes and 34 trimmed.
The largest buyer was Mirae Asset Global Investments, opening a new position worth an estimated $7.5M. The largest seller was Fine Capital Partners, exiting entirely with an estimated $4.76M sold.
- 118 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2017, up from 116 in Q1 2017.
- Funds reported $246M of Insys Therapeutics, Inc. stock for Q2 2017, up 13% quarter-over-quarter.
- 20 funds opened new Insys Therapeutics, Inc. positions in Q2 2017 and 18 closed out, a net change of +2 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2017 was Mirae Asset Global Investments, an estimated $7.5M added.
- The largest Insys Therapeutics, Inc. seller in Q2 2017 was Fine Capital Partners, an estimated $4.76M sold.
Based on aggregated 13F filings for Q2 2017.